Table 2 Medical and surgical therapy of 61 orthopedic implant infections due to S. agalactiae and outcomes of 54

Surgery

DAIR [n (%)]

 Performed on early infection (out of total DAIR)

 Performed on delayed or late infection

19/50 (38)

2/18 (11)

16/18 (89)

One-stage exchange arthroplasty [n (%)]

 Performed on early infection (out of total One-stage exchange arthroplasty)

 Performed on delayed or late infection

18/50 (36)

2/18 (11)

16/18 (89)

Two-stage exchange arthroplasty [n (%)]

10/50 (20)

Bone resection [n (%)]

1/50 (2)

Arthrodesis [n (%)]

1/50 (2)

Amputation [n (%)]

1/50 (2)

Antibiotic therapy

Post-operative intravenous (IV) therapy

 - Cefotaxime [n (%)]

 - Cefepime [n (%)]

 - Daptomycin [n (%)]

 - Ceftobiprole [n (%)]

13/34 (38)

5/34 (15)

12/34 (35)

5/34 (15)

IV duration (days) [med (IQR)] out of 33 patients

6 (7)

Post-operative per os therapy

 - Rifampin combined with other antibiotics than Levofloxacin^a

 - Levofloxacin combined with other antibiotics than Rifampin or alone

 - Rifampin-levofloxacin combination

6/53 (11)

12/53 (23)

31/53 (58)

Oral treatment duration (weeks) [med (IQR)] out of 54 patients

12 (8)

Outcomes with at least 1 year follow-up

n = 41

Remission [n (%)]

26 (63)

Relapse [n (%)]

1 (2)

Reinfection [n (%)]

5 (12)

Superinfection [n (%)]

3 (7)

Suppressive antibiotic therapy [n (%)]

 - Amoxicillin (n)

 - Clindamycin (n)

 - Doxycycline (n)

 - Dalbavancin-ertapenem combination (n)

8/41 (20)

4

1

1

2